2012 New Drug Approvals

From Medscape Oncology

Cancer Beats All Other Fields for 2012 New Drug Approvals 1. Axitinib (Inlyta, Pfizer) Drug monograph on Medscape Reference FDA Approves Axitinib for Advanced Renal Cell Cancer Medscape News, January 30, 2012 2. Vismodegib (Erivedge, Genentech) Drug monograph on Medscape Reference FDA Approves Vismodegib for Advanced Basal Cell Carcinoma Medscape News, January 30, 2012 3. Pertuzumab (Perjeta, Roche) Drug monograph on Medscape Reference Pertuzumab Approved for HER2 Breast Cancer Medscape News, June 11, 2012 4. Carfilzomib (Kyprolis, Onyx Pharmaceuticals) Drug monograph on Medscape Reference Carfilzomib Receives FDA Nod for Multiple Myeloma Medscape News, July 20, 2012 5. Ziv-aflibercept (Zaltrap) Drug monograph on Medscape Reference Aflibercept Approved for Colorectal Cancer in the US Medscape News, August 3, 2012 6. Enzalutamide (Xtandi, Astellas/Medivation) Drug monograph on Medscape Reference Enzalutamide Gets FDA Nod for Late-Stage Prostate Cancer Medscape News, August 31, 2012 7. Bosutinib (Bosulif, Pfizer) Drug monograph on Medscape Reference A 4th Option for CML: FDA Grants Approval for Bosutinib Medscape News, September 4, 2012 8. Regorafenib (Stivarga, Bayer) Drug monograph on Medscape Reference FDA Approves Regorafenib for Metastatic Colorectal Cancer Medscape News, September 27, 2012 9. Omacetaxine mepesuccinate (Synribo, Teva Pharmaceuticals) Drug monograph on Medscape Reference FDA Approves New Drug for Chronic Myelogenous Leukemia Medscape News, October 26, 2012 10. Cabozantinib (Cometriq, Exelixis) Drug monograph on Medscape Reference FDA Approves Cabozantinib for Medullary Thyroid Cancer Medscape News, November 29, 2012 11. Ponatinib (lclusig, Ariad) Drug monograph on Medscape Reference FDA Approves Ponatinib for Rare Leukemias Medscape News, December 14, 2012 Other Approvals The FDA approved another 3 agents for use in cancer patients this year, either for supportive care or for imaging. 1. Glucarpidase (Voraxaze, BTG International) Drug monograph on Medscape Reference FDA Approves Glucarpidase to Reduce Toxic Methotrexate Levels Medscape News, January 17, 2012 2. Tbo-filgrastim (TevaGrastim, Teva Pharma) - a biosimilar to Neupogen, Amgen Drug monograph on Medscape Reference FDA Approves Tbo-Filgrastim for Neutropenia Medscape News, August 29, 2012 3. FDA Approves PET Imaging Agent for Prostate Cancer Medscape News, September 12, 2012